What is Inventisbio?
Inventisbio is a specialized biopharmaceutical entity dedicated to the discovery and development of innovative therapeutic agents. The company maintains a robust focus on addressing major diseases, with a particular emphasis on tumor-related conditions, autoimmune disorders, and metabolic dysfunctions. Its operational strategy is anchored in the pursuit of synthetic lethal pathways, kinase inhibition, and the modulation of tumor driver genes. With a portfolio that includes two successfully launched products and a deep bench of candidates currently in clinical evaluation—including two core assets in phase III trials—Inventisbio demonstrates a sophisticated capability for translating complex biological research into viable clinical solutions. The firm's market position is defined by its commitment to precision medicine and its ability to navigate the regulatory and scientific hurdles inherent in modern drug development.
How much funding has Inventisbio raised?
Inventisbio has raised a total of $247M across 4 funding rounds:
Series A
$11M
Series B
$19M
Series C
$70M
Series D
$147M
Series A (2016): $11M with participation from Sinopharm Capital Management
Series B (2017): $19M led by OrbiMed
Series C (2019): $70M supported by OrbiMed, Shanghai Pudong Innotek Group, Advantech Capital, CMB International Capital, and Lilly Asia Ventures
Series D (2020): $147M featuring Dyee Capital, GL Ventures LLC, Janchor Partners Limited, AIHC Capital, E Fund Capital, Qiming Venture Partners, and Matrix Partner China
Key Investors in Inventisbio
OrbiMed
OrbiMed is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and diagnostics with a deep understanding of innovation cycles.
Lilly Asia Ventures
Lilly Asia Ventures is a leading biomedical venture capital firm that partners with entrepreneurs to develop breakthrough products that treat diseases and improve human health.
Advantech Capital
Advantech Capital is a private equity fund focused on innovation-driven growth capital within the TMT and healthcare sectors in China.
What's next for Inventisbio?
With the recent influx of capital, Inventisbio is strategically positioned to advance its phase III clinical trials toward potential commercialization. The company's roadmap focuses on the successful execution of these late-stage studies, which are pivotal for validating the efficacy and safety profiles of its core assets. Furthermore, the firm is expected to leverage its strengthened balance sheet to expand its preclinical pipeline, potentially exploring new therapeutic modalities that align with its existing expertise in kinase and synthetic lethal pathways. As the company moves closer to market entry for its late-stage candidates, the focus will likely shift toward building commercial infrastructure and establishing strategic partnerships to maximize the global reach of its innovative drug portfolio.
See full Inventisbio company page
